Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

ssed PFS and OS. Patients had a variety of cytogenetic abnormalities, including: 17p deletion (33 percent), 13q deletion (14 percent), trisomy 12 (12 percent), 11q deletion (20 percent) and 22 percent without any of the aforementioned abnormalities.

The ORR was 38 percent, with a 44 percent ORR in the 17p deletion group, 53 percent in patients with 13q deletion, 56 percent in the trisomy 12 group and 21 percent in the 11q deletion group. Patients without any of these abnormalities had an ORR of 27 percent.

Median PFS and OS for the whole group were 6.9 months and 30 months, respectively. In 17p deletion, patients' PFS was 7.1 months and OS was 19.1 months. A subanalysis of patients with 17p deletion who were also resistant to fludarabine (n=25), showed ORR of 28 percent and PFS and OS rates of 7.2 and 19.1 months, respectively. These results did not differ from those in fludarabine resistant patients categorized as having good risk cytogenetics.

Abstract #2095

CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p

In this analysis, researchers evaluated Campath in combination with the standard treatment regimen known as FCR (fludarabine, cyclophosphamide and rituximab) as front-line therapy to a high-risk group of CLL patients.

Of the 60 patients intended for analysis in the CFAR group, 48 were evaluated for response and follow-up at the time of this interim analysis. Within this group of 48 patients, 28 percent (n=13) had 17p deletion identified by FISH analysis prior to treatment. Treatment with Campath resulted in an ORR of 94 percent and a CRR of 69 percent. In patients with 17p deletion, treatment with Campath resulted in an ORR of 77 percent and a CRR of 54 percent.

CFAR treatment regimen was associated with more myelosuppression and fewer p
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... WAYNE, N.J., Dec. 16 MAQUET ... technologies, today announced that it has signed ... Novation, the industry,s leading supply contracting company, ... (EVH) Systems. The VASOVIEW products assist healthcare ... blocked coronary arteries using only small incisions. ...
(Date:12/16/2009)... VIEW, Calif., Dec. 16 Frost ... Zachary Bujnoch, looks forward to speaking at ... Summit taking place on January 9, 2010 ... on the emerging market of consumer-based digital ... services. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, ...
(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... major medical meeting showed that its lead compound ... no signs of the CNS-related side effects seen ... The studies also showed that GLYX-13,s antidepressant effects ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Women often opt to surgically remove their breasts ovaries to reduce cancer risk 9493 1Women often opt to surgically remove their breasts ovaries to reduce cancer risk 9493 2Women often opt to surgically remove their breasts ovaries to reduce cancer risk 9493 3Cooling treatment after cardiac arrest is cost effective Penn study shows 53796 1Cooling treatment after cardiac arrest is cost effective Penn study shows 53796 2UCLA welcomes startup to new incubator space at California NanoSystems Institute 13403 1UCLA welcomes startup to new incubator space at California NanoSystems Institute 13403 2UCLA welcomes startup to new incubator space at California NanoSystems Institute 13403 3
... Using 24-Hour Ambulatory BP MeasuresPARSIPPANY, N.J., May 8 ... the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual ... from the AZ OR(R) T rial ... ( AZTEC ) demonstrated that a stepwise amlodipine and ...
... May 8 , - Glivec(R) ... With KIT (CD117)-Positive Gastrointestinal Stromal Tumours,(GIST), who are at Significant ... - Use of Glivec(R) After Surgery Significantly Reduces ... Untreated After Surgery, 50% of patients Will Experience Their,Cancer Returning ...
Other Medicine Technology:New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 2New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 3New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 4New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 5New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 6New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 7New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 8New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 9Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 2Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 3Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 4Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 6
(Date:12/16/2009)... -- Health care sector revenue increased by 5.7 ... $1.66 trillion in 2007, according to new data ... classified under the North American Industry Classification System ... ,, These figures come from the 2008 ... , a series of tables which provides estimates ...
(Date:12/16/2009)... CHASE, Md., Dec. 16 New Enterprise ... firm, today announced that one of its portfolio ... agreement to be acquired by Ethicon, Inc., a ... for approximately $785 million (net of estimated cash ... technology company dedicated to designing, developing and commercializing ...
(Date:12/16/2009)... felt so good for "The Biggest Loser" Danny Cahill. ... to make smart choices everyday to help him stay ... that is an important part of living well. And ... of milk has nine essential nutrients like protein for ... and calcium and vitamin D for strong bones. ,, ...
(Date:12/16/2009)... a result of C3: Colorectal Cancer Coalition,s advocacy efforts, ... program is included in the final Fiscal Year 2010 ... program will research cancers, like colorectal cancer, that are ... cancer research programs run by the U.S. Army Medical ... million in funding for this new cancer research program ...
(Date:12/16/2009)... suggests it plays a role in reducing inflammation in ... A gene variant that plays a role in inflammation ... as well as adults who smoke. , Researchers also ... MMP12 gene had a lower risk of developing chronic ... on by smoking. , "The gene seems to be ...
Breaking Medicine News(10 mins):Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3
... imagination and more take cues from hues, study finds, , , ... Wear red. Want to be more creative at work? ... of British Columbia analyzed the effect of color on ... and creative tasks presented on computer screens set to either ...
... to educate retailers about the lawOLYMPIA, Wash., Feb. 5 ... has tripled since 2006, according to a new report. The ... 2008. That,s up from nine percent in 2007 and five ... ( www.doh.wa.gov ) is working with other state and local ...
... early detection of disease, A Su Salud revealed high ... participants and provided $55 million in free and low ... /PRNewswire/ -- CVS/pharmacy, the ... of "A Su Salud" (To Your Health) health fairs, ...
... from The University of Texas M. D. Anderson Cancer ... formation, and vascular endothelial growth factor expression are associated ... tumors. This data was presented in a poster session ... Meeting on Women,s Cancer. , Sex cord-stromal ovarian ...
... 5 Stephens Media LLC of,Las Vegas, Nevada ... Illinois to deliver Surgery Benefit Management to their ... surgical care and,personal savings through Healthplace America,s revolutionary ... date, the Healthplace,Surgery Benefit(TM) is the first -- ...
... for rehabilitation therapists remain strong. The shortage ... demand for physical therapists, occupational therapists, speech-language ... percent.KENNETT SQUARE, Pa., Feb 5 Workers ... experience low rates of unemployment and high ...
Other Medicine News:Health News:Color Can Affect How People Think and Act 2Health News:Color Can Affect How People Think and Act 3Health News:More Retailers Selling Tobacco to Minors 2Health News:More Retailers Selling Tobacco to Minors 3Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3Health News:Angiogenesis linked to poor survival in patients with rare type of ovarian cancer 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 3Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 4Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 2Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 3
... Weighing only 10 oz., the IQmark Digital ... diagnostic family. The IQmark Digital Spirometer meets or ... Society and is easy to use. It supplies ... a diagnostic Spirometer. This includes FEV6 that is ...
... only, medium-depth chemical peel. ... corrext for less pain ... revolutionary medical strength peel ... facilitate a deeper penetration ...
... a non-irritating rapid exfoliator. Lactic Acid is is ... and exfoliating agents in skin care products, as ... for a long period and want to improve ... metabolite, and combined with the chemical free style ...
Catalyst for skin rejuvenation. Rapidly exfoliates superficial skin problems....
Medicine Products: